W. McLean Provan - Concepedia

Author

W. McLean Provan

AstraZeneca (United Kingdom)

Also Known As

W. M. Provan, W. McLean Provan, W.M. Provan, W.McLean Provan, W.Mclean Provan, William M. Provan

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)Syngenta (United Kingdom)

About

W. McLean Provan is an author at AstraZeneca (United Kingdom) specializing in medicine, pharmacology, and oxidative stress.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	666
2	Biochemistry	6	6	534
3	Natural Sciences	3	3	355
4	Public Health	1	1	38
5	Allergy	1	1	38

W. McLean Provan

Publications

968

Citations

H-Index

Page 1

	Year	Citations
The discovery and structural requirements of inhibitors of <i>p</i>-hydroxyphenylpyruvate dioxygenase David L. Lee, Michael P. Prisbylla, Thomas H. Cromartie, Weed Science Secondary MetaboliteChemical BiologyToxicological MechanismOxidative StressHppd Herbicide	1997	210
Species differences in response to trichloroethylene M.S. Prout, W. McLean Provan, T. Green Toxicology and Applied Pharmacology Environmental ChemistryPesticide ResistanceSpecies DifferencesEcotoxicologyEnvironmental Toxicology	1985	144
Inhibition of 4-Hydroxyphenylpyruvate Dioxygenase by 2-(2-Nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-Chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione Martin K. Ellis, Alison C. Whitfield, Lesley A. Gowans, Toxicology and Applied Pharmacology Bioorganic ChemistryAldehyde DehydrogenaseBiochemistryMedicineNatural Sciences	1995	113
Pharmacokinetics and pharmacodynamics of NTBC (2‐(2‐nitro‐4‐fluoromethylbenzoyl)‐1,3‐cyclohexanedione) and mesotrione, inhibitors of 4‐hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers Michael G. Hall, Martin F. Wilks, W. McLean Provan, British Journal of Clinical Pharmacology	2001	111
Effect of intestinal microflora on the urinary metabolic profile of rats: a 1 H-nuclear magnetic resonance spectroscopy study Rebecca E. Williams, H. W. Eyton-Jones, Mark J. Farnworth, Xenobiotica Gastrointestinal PharmacologyDigestive TractM-hppa LevelsOxidative StressUrinary Metabolic Profile	2002	94
Predicting Cancer Risk from Vinyl Chloride Exposure with a Physiologically Based Pharmacokinetic Model Richard H. Reitz, Michael L. Gargas, Melvin E. Andersen, Toxicology and Applied Pharmacology Vinyl Chloride ExposureOncologyPharmacokinetic ModelingPredictive ToxicologyPreclinical Drug Evaluation	1996	75
Tissue Distribution of 2-(2-Nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione (NTBC): Effect on Enzymes Involved in Tyrosine Catabolism and Relevance to Ocular Toxicity in the Rat Edward A. Lock, Peter Gaskin, Martin K. Ellis, Toxicology and Applied Pharmacology Ocular ToxicityBiochemistryOphthalmologyMedicineTissue Distribution	1996	52
The Integrated Use of Alternative Approaches for Predicting Toxic Hazard Martin D. Barratt, José V. Castell, M. Chamberlain, Alternatives to Laboratory Animals Environmental Safety LaboratorySafety ScienceToxicology TestingFood ToxicologyRisk Management	1995	38
Tyrosinemia produced by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) in experimental animals and its relationship to corneal injury Edward A. Lock, Peter Gaskin, M. Ellis, Toxicology and Applied Pharmacology OphthalmologyExperimental OphthalmologyMedicineCorneal DystrophyGlaucoma	2006	33
Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) and its effect on enzymes involved in tyrosine catabolism in the mouse Edward A. Lock, Peter Gaskin, Martin K. Ellis, Toxicology BiochemistryPhysiologyTissue DistributionCatabolismMetabolism	2000	33

Page 1